Supplementary Tables 1 - 2 from Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 121K, Table 1. Supplemental Table 1. Comparison of the Patients Analyzable for VEGFA Amplification to All Patients Enrolled on E2100 Table 2. Estimated Progression Free Survival treatment hazard ratios (arm A vs. arm B) and 95% confidence intervals for various subsets. Comparison between the cases analyzable for VEGFA amplification and all cases in E2100
Authors: Bryan P. Schneider, Robert J. Gray, Milan Radovich, Fei Shen, Gail Vance, Lang Li, Guanglong Jiang, Kathy D. Miller, Julie R. Gralow, Maura N. Dickler, Melody A. Cobleigh, Edith A. Perez, Tamara N. Shenkier, Kirsten Vang Nielsen, Sven Müller, Ann Thor, George W. Sledge, Joseph A. Sparano, Nancy E. Davidson, Sunil S. Badve
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361968855